Organoids Market Size Report | Analysis and Forecast 2030

[Research Report] The organoids market was valued at US$  2,507.28  million in 2022 and is expected to reach US$ 12,206.15 million by 2030. It is anticipated to register a CAGR of 21.9% during 2022–2030.

Market Insights and Analyst View:

The organoids market size is growing rapidly due to the increasing demand for tumor modeling and biobanking, growing adoption of personalized drugs, and rising focus on developing alternatives for animal testing models. However, issues related to the incorporation of organoids into existing workflows and the shortage of skilled professionals hinder market growth.

Organoids are microscopic and self-organizing 3D structures grown from stem cells in vitro. They review various structural and functional characteristics of their in vivo counterpart organs. This multipurpose technology has led to several novel human cancer models. It is now possible to create indefinitely expanding organoids starting from the tumor tissue of individuals suffering from a range of carcinomas. Alternatively, CRISPR-based gene modification allows the engineering of organoid models of cancer by introducing a combination of cancer gene alterations to normal organoids. Tumor organoids, combined with immune cells and fibroblasts, become a model for the cancer microenvironment, enabling immune-oncology applications. Also, recent studies have proved that organoids have a place in personalized medicine approaches. The study will enable the development of prevention, progression, and treatment strategies. The commercialization of the new technology will boost the market value in the coming years.

Growth Drivers and Challenges:

Precision medicine or personalized medicine is a medical model that practices medical procedures or drugs tailored to the individual patient based on the target response or disease risk. According to a study published by Personalized Medicine Coalition (PMC), personalized medicines accounted for only 5% of the new FDA-approved molecular entities in 2005, whereas they accounted for more than 25% in 2016. Additionally, about 42% of all compounds and nearly 73% of oncology compounds in the product pipeline have the potential to be precision medicines. Moreover, biopharmaceutical companies nearly doubled their research and development investment in personalized drugs over the past five years, likely increasing by around 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years. According to the latest report by the PMC (published in 2021), in the US, the number of personalized medicines in the market has risen from about 132 in 2016 to 286 in 2020. The data was shared by tracking the number of personalized medicines since 2008 by the PMC. These advantages focus on the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.

As the manufacturing of organoids is capital- and time-intensive, the adoption of organoids in ongoing drug screening and discovery activities is limited. Moreover, a lack of 3D cell culture research infrastructure and various technological challenges are hindering the incorporation of organoids into existing research workflows. Although organoids show significant potential in miniaturizing systems and reducing drug discovery and development costs, it is expected to take a few years for this technology to replace conventional models completely. Until this scenario continues, organoid manufacturers will witness sporadic growth and may be sidelined by traditional technology providers.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Organoids Market: Strategic Insights

Organoids Market

• 
  CAGR (2022 - 2030)

  21.9%
• Market Size 2022
  US$ 2.51 Billion
• Market Size 2030
  US$ 12.21 Billion

Market Dynamics

GROWTH DRIVERS

• Increasing Demand for Tumor Modeling and Biobanking
• Growing Adoption of Personalized Drug
• Rising Focus on Developing Alternatives for Animal Testing Models

FUTURE TRENDS

• Combining Organoid with Organ-On-A- Chip

OPPORTUNITIES

• Focus on Drug Discovery Activities

Key Players

• STEMCELL Technologies Inc
• Cellesce Ltd
• Hubrecht Organoid Technology
• Definigen
• Organoid Therapeutics
• PeproTech, Inc
• Thermo Fisher Scientific Inc
• Corning Inc
• Merck KGaA

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Organ Type

• Intestine
• Liver
• Stomach
• Pancreas
• Lung
• Brain
• Kidney
• Others

Application

• Development of Biology Disease
• Pathology of infectious Disease
• Regenerative Medicines
• Drug Discovery and Personalized Medicine
• Drug Toxicity and Efficacy Testing
• Others

Source

• Pluripotent Stem Cell and Organ Specific Adult Stem Cell

Type

• Instruments
• Consumables
• Services

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Report Segmentation and Scope:

The organoids market is segmented based on organ type, application, source, type, and geography. The market is classified into intestine, liver, stomach, pancreas, lung, brain, kidney, and others based on organ type. The overall market growth by organ type is attributed to growing product launches and increasing demand for oncology research.

The market is classified into instruments, consumables, and services based on type. In 2022, the consumables segment held the largest market share and is expected to grow at the fastest rate during the coming years. Based on geography, the market is divided into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:

Based on organ type, the organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. In 2022, the intestine segment held the largest market share and is estimated to grow at a significant CAGR during 2022–2030. Intestinal organoids are 3D in vitro models of the human intestinal epithelium that can be used in patient-specific in vitro research to study the properties of the intestinal epithelium. The presence of well-established and budding players worldwide widely drives the organoids market.

Based on application, the organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. In 2022, the developmental biology disease segment held the largest market share by application. It is expected to grow at the fastest rate during the coming years.

Based on source, the organoids market is segmented into pluripotent stem cells and organ-specific adult stem cell. In 2022, the pluripotent stem cells segment held a larger market share and is expected to grow at a faster rate during the coming years.

The organoids market is segmented into instruments, consumables, and services based on type. In 2022, the consumables segment held the largest market share and is expected to grow at the fastest rate during the coming years.

Regional Analysis:

Based on geography, the organoids market is divided into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. North America is the largest contributor to the market growth, and Asia Pacific is the fastest-growing region. The growth of the market in North America is attributed to factors including higher healthcare expenditure, advancements in medical technology, and ongoing research in universities in the region. Based on countries analyzed in North America, the US is the largest market share holder. Increasing research activities on organoids are expected to drive the market in the region during the forecast period. For instance, the US-based Cincinnati Children’s Hospital Medical Center established a Center for Stem Cell and Organoid Medicine (CuSTOM). CuSTOM integrated over 15 joint research faculty groups using various organoid platforms in collaboration with a few industrial and philanthropic partners. The initial aims of CuSTOM include developing a gastrointestinal and liver organoid system for drug testing and transplantation based on its strong endoderm development expertise.

Industry Developments and Future Opportunities:

Various initiatives by key players operating in the organoids market are listed below:

1. In February 2023, Thermo Fisher Scientific, which is a US-based company, and Celltrio - South Korea-based, collaborated on a fully automated cell culture system useful for biotherapeutics customers. This collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell automation platform to meet market demand for high-throughput automated cell line culturing and maintenance.
2. In August 2021, STEMCELL Technologies, which is a based company, and Hubrecht Organoid Technology (HUB) signed a contract to use tissue-derived organoids—including lung, liver, and intestinal organoids—in preclinical toxicology screening as well as for non-cancer drug development services that are offered by the Contract Assay Services, which is part of STEMCELL company.

Organoids Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

COVID-19 Impact:

The companies engaging in the organoid market witnessed a slight adverse impact on their products and services in early 2020, as most service providers prioritized actions for helping the critical work of consumers involved in COVID-19, such as giving a range of high-end COVID-19-related reassigning research and development resources and research tools for manufacturing essential products for SARS-Cov-2, expanding the supply chain, and making flexibility to support expanded demand for enduring products applied for SARS-CoV-2/COVID-19 research, and entering into discussions and collaborations across the UK, the US, and China concentrated on SARS-CoV-2 diagnostics, drugs, and vaccines development. The COVID-19 pandemic caused unintended consequences of severe delays in diagnosing and treating various diseases, including liver and kidney diseases.

Competitive Landscape and Key Companies:

A few prominent players operating in the organoids market are STEMCELL Technologies Inc., Hubrecht Organoid Technology, Definigen, Cellesce Ltd, Organoid Therapeutics, 3Dnamics Inc., Corning Inc., Merck KGaA, Thermo Fisher Scientific Inc., and InSphero. These leading companies focus on new product launches and geographic expansions to meet the higher consumer demand worldwide and increase their product offerings in specialty portfolios. Their global presence allows them to serve a large set of customers, subsequently allowing them to expand their market share.